Earnings per share for the last twelve months: Protara Therapeutics Inc (TARA)
Reliance on external partners for clinical trials minimizes operational risks, which is reflected in the earnings per share over the last four quarters on the GURU.Markets terminal linear chart, where -1.40 records a new level. Profit growth is based on the market launch of therapies for rare pathologies, while its status as a reputable developer of innovative oncology treatments strengthens the market position of Protara Therapeutics (TARA).
Analytical breakdowns for Protara Therapeutics Inc (TARA)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity Protara Therapeutics|TARA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Protara|TARA - Company Cumulative Debt|Debt to Book Value Protara Therapeutics, Inc.|TARA - Amount of Long-Term Liabilities|Company Short-Term Debts Protara Therapeutics|Quick Liquidity protaratx.com
- net income and valuation multiples indicators:
TARA - Final Profit|Projected Future Earnings Protara Therapeutics|TARA - P/E Multiple|Projected Price to Earnings Protara Therapeutics, Inc.|TARA - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Protara Therapeutics, Inc.|TARA - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Protara Therapeutics|TARA - Earnings per share for the trailing year|Quarterly EPS earnings growth protaratx.com|TARA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Protara Therapeutics
- revenue and sales proceeds data:
Basic company analysis:Protara Therapeutics - TARA
For Protara Therapeutics (TARA), which focuses on therapies for rare oncological diseases, the 12-month rolling income per share reflects the efficiency of clinical program management through the lens of net profit per share. This metric is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to differentiate sustainable business growth from short-term reductions in operating expenses.
Who Protara Therapeutics competes with
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Earnings per share for the last twelve months Bicara Therapeutics Inc. (BCAX)|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca ERAS|Earnings per share for the trailing year DCTH|YMAB - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Aura Corp|CADL (candeltx.com) - Net earnings per share for the last 12 months|ARAY: Earnings per share for the last four quarters|SLS (SELLAS Life Sciences Group, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Actuate Therapeutics Inc.|Earnings per share for the last twelve months Citius Oncology, Inc (CTOR)|HURA (tuhurabio.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) FATE (Fate Therapeutics, Inc.)|Net earnings per share (EPS TTM) Aadi Bioscience, Inc. WHWK|TCRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year CSBR (Champions Oncology)|XBIT (xbiotech.com) - Net earnings per share for the last 12 months|CVM: Earnings per share for the last four quarters|OSTX (OS Therapies Incorporated) - Net earnings per share (EPS TTM)|RADX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ARTV|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Pharma VERU|Earnings per share for the trailing year TPST|Xilio - Net earnings per share (EPS TTM)|RENB - Net earnings per share (EPS TTM)|muraloncology.com (MURA) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months KAPA (Kairos Pharma)|OKUR (OnKure Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CytoMed GDTC|Net earnings per share for the last 12 months CRIS (Curis, Inc.)|Net earnings per share (EPS TTM) apollomicsinc.com (APLM)|Tharimmune - Net earnings per share for the last 12 months|Earnings per share for the last four quarters ADVB (Advanced Biomed Inc.)|Genprex, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Calidi Biotherapeutics CLDI|SBFM: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Xenetic Biosciences, Inc.|Earnings per share for the last twelve months Salarius Pharmaceuticals, Inc.|Purple Biotech Ltd (PPBT) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months AONC (American Oncology Network)|Earnings per share for the last four quarters BGNE|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics)|Net earnings per share (EPS TTM) elevationoncology.com ELEV|ICAD - Earnings per share for the last twelve months|Earnings per share for the trailing year IKNA (Ikena Oncology, Inc.)|NTBL: Net earnings per share (EPS TTM)|Viracta Therapeutics, Inc. (VIRX) - Net earnings per share (EPS TTM)|MOR (MorphoSys AG) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months nayabiosciences.com (NAYA)|Net earnings per share (EPS TTM) AAPGV
